<DOC>
	<DOCNO>NCT01875874</DOCNO>
	<brief_summary>This phase 2 study develop evaluate effect ELAD overall survival ( OS ) subject acute liver failure ( ALF ) compare matched historical control .</brief_summary>
	<brief_title>Safety Efficacy ELAD Treat Acute Liver Failure ( ALF )</brief_title>
	<detailed_description>VTI-212 open-label , multicenter , historically-controlled study subject acute liver failure ( ALF ) . Approximately 40 subject meet eligibility requirement study receive ELAD treatment addition standard care treatment ALF . The outcomes subject compare matched historical control draw exist database . Subjects undergo ELAD treatment minimum 3 day ( 72 hour ) . It recommend ELAD treatment continue 10 day ( 240 hour ) . Following ELAD treatment , subject continue standard medical therapy define institution follow Study Day 28 . Subjects ' diagnosis ALF attribute one following : 1 . FHF ( acute liver failure preexist liver disease ) ; 2 . Primary Graft Non-Function ( PNF ) ; 3 . Surgically-Induced Liver Failure ( include subject small size liver transplant , live donor liver transplant , subject risk ALF follow liver cancer surgery . Screening evaluation assessment complete subject review inclusion/exclusion criterion . Enrollment define time study entry ( Hour 0 , Study Day 1 , study baseline ) inclusion ITT population . Subjects evaluate throughout 28-day study period . If standard medical therapy , define institution protocol consistent discharge subject home , subject discharge . Prior discharge , subject advise attend follow-up visit . An extension study , VTI-212E , provide additional ELAD survival data , available , VTI-212 study termination ( last surviving enrol ELAD subject completes Study Day 28 ) . This registry protocol segment VTI-212 extend safety monitoring period 5 year assess survival , incidence characterization tumor ( particular hepatocellular tumor ) , incidence liver transplant , ass quality life use standard , validated questionnaire .</detailed_description>
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>Liver Failure , Acute</mesh_term>
	<mesh_term>Liver Extracts</mesh_term>
	<criteria>1 . Weight ≥ 40 kg ; 2 . Age ≥ 18 ; 3 . Diagnosis ALF attribute one following : 1 . FHF ( acute liver failure preexist liver disease , see ) ; 2 . Primary Graft NonFunction ( PNF ) ; 3 . SurgicallyInduced Liver Failure ( include subject small size liver transplant , live donor liver transplant , subject risk ALF follow liver cancer surgery ) ; 4 . Subjects must list transplant time Enrollment , list , opinion Investigator unlikely transplant within 72 hour ; 5 . Subject legally authorize representative must provide Informed Consent VTI212 Followup Registry VTI212E . SUBJECTS WITH FHF MUST MEET ONE OF THE FOLLOWING CRITERIA : 6 . Known acetaminophen ingestion diagnostic serum level , least one following : 1 . Prothrombin time ( PT ) &gt; 100 second [ International Normalized Ratio ( INR ) &gt; 6.5 ] , OR 2 . Encephalopathy Grade 3 4 AND ARTERIAL AMMONIA &gt; 100 umol/liter least one following : i. Arterial pH &lt; 7.30 ≥ 24 hour drug ingestion volume resuscitation ; ii . Renal failure document urine output &lt; 0.5 mL/kg/hr precede 12 hour ; iii . Creatinine &gt; 2.5 mg/dL ; OR 7 . Nonacetaminopheninduced FHF Encephalopathy Grade 3 4 arterial ammonia &gt; 100 umol/liter , least two follow : 1 . Viral Hepatitis ( A , B C ) drug ( nonacetaminophen ) induce FHF 2 . Serum bilirubin &gt; 17 mg/dL 3 . Subject &gt; 40 year old 4 . PT &gt; 50 second ( INR &gt; 3.5 ) 5 . Jaundice encephalopathy time ≥ 7 day 1 . Cerebral Perfusion Pressure ≤ 40 mm Hg 1 hour longer measure intracranial pressure ( ICP ) monitor . ( NOTE : In case ICP monitor placement perform prior study enrollment , exclusion criterion apply ) ; 2 . Chronic liver disease ( e.g. , compensated cirrhosis etiology , chronic hepatitis , nonalcoholic steatohepatitis , cholestatic liver disease , metabolic liver disease ) ( NOTE : steatosis exclusion criterion ) ; 3 . Acute clinical symptom , Investigator 's opinion , likely result death within 48 hour enrollment ; 4 . Evidence infection unresponsive antibiotic ( e.g . increase tissue involvement relative initial diagnosis , clinical worsen symptom ) indicate follow : 1 . Presence sepsis septic shock ; OR 2 . Positive blood culture ( bacteremia , fungemia ) within 72 hour prior Enrollment ; OR 3 . Presence spontaneous bacterial peritonitis 2 day prior Enrollment ; OR 4 . Clinical radiological sign pneumonia . 5 . Concomitant disease include chronic congestive heart failure , severe vascular disease , emphysema , AIDS , cancer ( except nonmelanoma skin cancer ) , acute fattyliver disease , hepatitis due herpes virus BuddChiari syndrome . ( NOTE : case subject enrol due surgeryinduced liver failure ( SILF ) original cause surgery criterion exclusion ) ; 6 . Portal hypertension ; 7 . Liver dysfunction due trauma ; 8 . Irreversible brain death ; 9 . Platelet count &lt; 30,000/mm3 [ NOTE : Subject may include physician 's discretion platelet count exceed 30,000/mm3 time initiation therapy ( even value follow platelet transfusion ) manage administration blood product ] 10 . Cardiovascular SOFA score &gt; 3 ; 11 . Stroke intracranial hemorrhage ; 12 . Seizures uncontrolled medication ; 13 . Acute myocardial infarction ; 14 . Lung disease define PaO2 ≤ 60 mm Hg FiO2 ≥ 0.6 , correct medical management [ include continuous venovenous hemofiltration ( CVVH ) indicate ] ventilation Positive End Expiratory Pressure ( PEEP ) &gt; 8cm H2O ; 15 . Acute Respiratory Distress Syndrome ; 16 . Pregnancy determine betahuman chorionic gonadotropin ( βhCG ) result ; 17 . ≤ 2 week postpartum ; 18 . Participation another investigational drug , biologic , device study within one month enrollment , except observational study ( observational study set affect safety and/or efficacy VTI212 clinical trial ) ; 19 . Prior ELAD therapy ; 20 . Has Do Not Resuscitate Do Not Intubate ( DNR/DNI ) directive ( local equivalent ) Advanced Directive limit Standard Care place ( DNR/DNI criterion applicable UK ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>liver failure</keyword>
	<keyword>acute liver failure</keyword>
	<keyword>fulminant hepatic failure</keyword>
	<keyword>primary graft non-function</keyword>
	<keyword>surgically-induced liver failure</keyword>
	<keyword>ELAD</keyword>
	<keyword>ALF</keyword>
	<keyword>FHF</keyword>
	<keyword>PNF</keyword>
</DOC>